Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL152161 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL14889921 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL155229 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL29670877 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL14890072 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL8836139 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL14890074 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL14889920 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL8836145 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL25869247 | 1.00 | FAAH (0.53) | FAAHKDM4EUSP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042541-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| EP-3757090-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024094098-A1 | COMPOUND FOR DELIVERY SYSTEM AND USE THEREOF | 益杰立科(上海)生物科技有限公司 | 2024-05-10 | — | — | WO | disclosed |
| US-20240042039-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-08 | — | — | US | disclosed |
| US-20230381319-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-11-30 | — | — | US | disclosed |
| EP-4241767-A2 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2023-09-13 | — | — | EP | disclosed |
| US-11712476-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-01 | — | — | US | disclosed |
| EP-3757090-A9 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2023-07-19 | — | — | EP | disclosed |
| US-20220023427-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-01-27 | — | — | US | disclosed |
| EP-3808177-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2021-04-21 | — | — | EP | disclosed |
| WO-2010054406-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054401-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054405-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010048536-A2 | PROCESSES FOR PREPARING LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100104629-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100076055-A1 | Cationic Lipids and Uses Thereof | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100055169-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2009132131-A1 | AMINO LIPID BASED IMPROVED LIPID FORMULATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009129387-A2 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129395-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104629-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | FAAH 2351/4885KDM4E 4752/4885USP2 4459/4885 |
| US-20230381319-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | SGMS2, SGMS1, PHOSPHO1 | FAAH 517/4885KDM4E 2940/4885USP2 3160/4885 |
| US-20100076055-A1 | Cationic Lipids and Uses Thereof | LIPA, SGMS2, SGMS1 | FAAH 2351/4885KDM4E 4752/4885USP2 4459/4885 |
| US-12042541-B2 | Lipids and compositions for the delivery of therapeutics | PHOSPHO1, MBOAT1, SGMS1 | FAAH 550/4885KDM4E 1867/4885USP2 3230/4885 |
| US-20220023427-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | SGMS2, APOB, PHOSPHO1 | FAAH 1138/4885KDM4E 1410/4885USP2 2329/4885 |
| US-11712476-B2 | Lipids and compositions for the delivery of therapeutics | SGMS2, APOB, PHOSPHO1 | FAAH 1138/4885KDM4E 1410/4885USP2 2329/4885 |
| US-20240042039-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | PHOSPHO1, MBOAT1, SGMS1 | FAAH 550/4885KDM4E 1867/4885USP2 3230/4885 |
| US-20100055169-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | FAAH 2351/4885KDM4E 4752/4885USP2 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.